The Institute of Liver Disease & Transplantation, Dr Rela Institute & Medical Centre, Bharath Institute of Higher Education and Research, Chennai, India.
Am J Transplant. 2022 Dec;22(12):3143-3145. doi: 10.1111/ajt.17165. Epub 2022 Aug 17.
Post-coronavirus disease 2019 (COVID-19) cholangiopathy (PCC) is a new entity observed in patients recovering from severe COVID-19 pneumonia. Most patients recover with cholestasis improving over a period of time. In some patients, cholestasis is severe and persists or progresses to liver failure necessitating liver transplant. We present a previously healthy 50-year-old man who developed PCC with peak total bilirubin of 42.4 mg/dl and did not improve with medical management. He underwent living donor auxiliary right lobe liver transplantation. He recovered well after transplant and remains asymptomatic at 6 months follow-up with good graft function and recovering function in native liver remnant.
新冠病毒病 2019 后(COVID-19)胆管病(PCC)是在严重 COVID-19 肺炎康复患者中观察到的一种新病症。大多数患者的胆汁淤积会随着时间的推移而改善,从而康复。但在一些患者中,胆汁淤积严重且持续存在或进展为肝衰竭,需要进行肝移植。我们报告了一位之前健康的 50 岁男性,他患有 PCC,总胆红素峰值为 42.4mg/dl,并且在药物治疗后没有改善。他接受了活体供体辅助右叶肝移植。他在移植后恢复良好,在 6 个月的随访中无症状,移植物功能良好,剩余的固有肝脏功能也在恢复。